KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Guardant Health (GH) Research & Development (2017 - 2026)

Guardant Health's Research & Development history spans 9 years, with the latest figure at $98.3 million for Q4 2025.

  • On a quarterly basis, Research & Development rose 5.05% to $98.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $364.2 million, a 4.73% increase, with the full-year FY2025 number at $364.2 million, up 4.73% from a year prior.
  • Research & Development hit $98.3 million in Q4 2025 for Guardant Health, up from $90.0 million in the prior quarter.
  • Over the last five years, Research & Development for GH hit a ceiling of $106.6 million in Q4 2022 and a floor of $55.5 million in Q1 2021.
  • Historically, Research & Development has averaged $85.8 million across 5 years, with a median of $88.0 million in 2025.
  • Biggest five-year swings in Research & Development: skyrocketed 95.8% in 2021 and later dropped 15.69% in 2023.
  • Tracing GH's Research & Development over 5 years: stood at $73.0 million in 2021, then surged by 45.96% to $106.6 million in 2022, then fell by 15.69% to $89.9 million in 2023, then increased by 4.1% to $93.5 million in 2024, then grew by 5.05% to $98.3 million in 2025.
  • Business Quant data shows Research & Development for GH at $98.3 million in Q4 2025, $90.0 million in Q3 2025, and $87.4 million in Q2 2025.